Equities

Champions Oncology Inc

Champions Oncology Inc

Actions
Health CareHealth Care Providers
  • Price (USD)4.64
  • Today's Change0.13 / 2.88%
  • Shares traded5.92k
  • 1 Year change-16.85%
  • Beta0.5121
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Champions Oncology Inc's revenues fell -6.90%from 53.87m to 50.16m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 36.38% reduction in net income from a loss of 5.34m to a larger loss of 7.28m.
Gross margin44.27%
Net profit margin-6.58%
Operating margin-6.73%
Return on assets-12.39%
Return on equity-432.46%
Return on investment-44.43%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Champions Oncology Inc fell by 7.50m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 6.14m for operations while cash used for investing totalled 836.00k.
Cash flow per share-0.1116
Price/Cash flow per share--
Book value per share-0.0244
Tangible book value per share-0.0491
More ▼

Balance sheet in USDView more

Champions Oncology Inc has a Debt to Total Capital ratio of 33,300.00%.
Current ratio0.6876
Quick ratio--
Total debt/total equity--
Total debt/total capital333.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.